

THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Previously presented): A method of modulating an immune response to a second antigen in an individual, comprising co-administering to the individual

(i) a complex comprising an immunomodulatory polynucleotide covalently conjugated to a first antigen and

(ii) a second antigen

wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the complex and the second antigen are administered at the same site in the individual and wherein the complex is administered in an amount sufficient to modulate an immune response in the individual to the second antigen.

Claims 2-12 (Cancelled)

Claim 13 (Original): The method of claim 1, wherein the first antigen is an allergen.

Claim 14 (Original): The method of claim 1, wherein the first antigen is a conserved polypeptide of a virus.

Claim 15 (Original): The method of claim 14, wherein the conserved viral polypeptide is influenza nucleocapsid protein.

Claim 16 (Original): The method of claim 14, wherein the conserved viral polypeptide is human immunodeficiency virus (HIV) gag protein.

Claim 17 (Original): The method of claim 1, wherein the first antigen is a carrier molecule.

Claim 18 (Original): The method of claim 17, wherein the carrier molecule is diphtheria toxin mutant (CRM 197).

Claim 19 (Original): The method of claim 17, wherein the carrier molecule is diphtheria toxoid.

Claim 20 (Original): The method of claim 1, wherein the first antigen is associated with a carrier molecule.

Claim 21 (Original): The method of claim 1, wherein the immune response is modulated by stimulating a Th1 response to the second antigen.

Claim 22 (Previously presented): The method of claim 21, wherein production of second antigen-specific Th1-associated antibodies is stimulated.

Claim 23 (Original): The method of 21, wherein interferon gamma production is stimulated.

Claim 24 (Cancelled)

Claim 25 (Previously presented): The method of claim 1, wherein the ISS comprises the sequence 5'-TCG-3'.

Claim 26 (Previously presented): The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine-3'.

Claim 27 (Original): The method of claim 26, wherein the ISS comprises the sequence 5'-AACGTT-3'.

Claim 28 (Original): The method of claim 26, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.

Claim 29 (Original): The method of claim 26, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.

Claim 30 (Original): The method of claim 26, wherein the ISS comprises a sequence selected from the group consisting of AACGTTCC, AACGTTTCG, GACGTTCC, and GACGTTTCG.

Claim 31 (Original): The method of claim 29, wherein the ISS comprises the sequence TGACTGTGAACGTTTCGAGATGA (SEQ ID NO:1).

Claim 32 (Original): The method of claim 1, wherein the individual is a mammal.

Claim 33 (Original): The method of claim 32, wherein the mammal is human.

Claims 34-36 (Cancelled)

Claim 37 (Previously presented): A composition comprising

(i) a complex comprising an immunomodulatory polynucleotide covalently conjugated to a first antigen and

(ii) a second antigen,

wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', and wherein the first antigen is a viral conserved polypeptide and the second antigen is a viral variable polypeptide.

Claim 38 (Previously presented): The composition of claim 37, wherein the first antigen is influenza nucleocapsid protein.

Claim 39 (Previously presented): The composition of claim 37, wherein the first antigen is human immunodeficiency virus (HIV) gag protein.

Claim 40 (Previously presented): A composition comprising

(i) a complex comprising an immunomodulatory polynucleotide covalently conjugated to a first antigen and

(ii) a second antigen,

wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', and wherein the first antigen is an allergen.

Claim 41 (Previously presented): The composition of claim 40, wherein the allergen is Amb a I.

Claim 42 (Previously presented): The method of claim 13, wherein the allergen is Amb a I.

Claim 43 (Withdrawn): A method of treating an allergy in an individual, comprising administering to the individual an immunomodulatory polynucleotide comprising an immunostimulatory sequence (ISS) and a first allergen with a second allergen, wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the polynucleotide and the first allergen are proximately associated and wherein the polynucleotide and first allergen are administered in an amount sufficient to stimulate a Th1 immune response in the individual to the second allergen.

Claim 44 (Withdrawn): The method of claim 43, wherein the first allergen is Amb a I.

Claim 45 (Withdrawn): A method of vaccinating an individual, comprising administering to the individual an immunomodulatory polynucleotide comprising an immunostimulatory sequence (ISS) and a first antigen with a second antigen, wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the polynucleotide and the first antigen are proximately associated and wherein

the polynucleotide and first antigen are administered in an amount sufficient to stimulate an immune response in the individual to the second antigen.

Claim 46 (Withdrawn): The method of claim 45, wherein the first antigen is a conserved polypeptide of a virus.

Claim 47 (Withdrawn): The method of claim 46, wherein the conserved viral polypeptide is influenza nucleocapsid protein.

Claim 48 (Withdrawn): The method of claim 46, wherein the conserved viral polypeptide is human immunodeficiency virus (HIV) gag protein.

Claim 49 (Withdrawn): The method of claim 45, wherein the first antigen is a carrier molecule.

Claim 50 (Withdrawn): The method of claim 49, wherein the carrier molecule is diphtheria toxin mutant (CRM 197).

Claim 51 (Withdrawn): The method of claim 49, wherein the carrier molecule is diphtheria toxoid.

Claim 52 (Withdrawn): The method of claim 45, wherein the first antigen is associated with a carrier molecule.

Claim 53 (Cancelled)